IFM Investors Pty Ltd Acquires 23,941 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

IFM Investors Pty Ltd grew its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 11.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 231,028 shares of the company's stock after acquiring an additional 23,941 shares during the period. IFM Investors Pty Ltd's holdings in Teva Pharmaceutical Industries were worth $3,551,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after acquiring an additional 19,242,468 shares during the period. Duquesne Family Office LLC raised its position in shares of Teva Pharmaceutical Industries by 530.1% during the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after buying an additional 7,569,450 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Teva Pharmaceutical Industries by 472.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock valued at $96,078,000 after buying an additional 5,186,592 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of Teva Pharmaceutical Industries by 416.0% during the first quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock valued at $91,973,000 after buying an additional 4,824,247 shares during the last quarter. Finally, Marshall Wace LLP raised its position in shares of Teva Pharmaceutical Industries by 87.8% during the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock valued at $113,625,000 after buying an additional 2,410,420 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president directly owned 9,989 shares of the company's stock, valued at $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.55% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TEVA shares. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective for the company. Finally, The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $24.13.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded down $0.20 during mid-day trading on Tuesday, hitting $16.65. 10,795,815 shares of the stock were exchanged, compared to its average volume of 12,199,727. The company has a market cap of $19.10 billion, a P/E ratio of -14.48, a PEG ratio of 0.87 and a beta of 0.60. The stock's fifty day simple moving average is $17.03 and its two-hundred day simple moving average is $17.28. The company has a debt-to-equity ratio of 2.59, a quick ratio of 0.74 and a current ratio of 1.03. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. The company had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The company's revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the business posted $0.48 earnings per share. As a group, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.